circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
=== 2000–2011: Established actor and diversification === In 2000, Carrey reteamed with the Farrelly brothers, who had previously directed him in Dumb and Dumber, for the black comedy film Me, Myself & Irene, a film that received mixed reviews but enjoyed box office success. Carrey played the role of state trooper Charlie Baileygates, who has multiple personalities and romances a woman portrayed by Renée Zellweger. That same year, Carrey starred in the second highest-grossing Christmas film of all time, How the Grinch Stole Christmas, playing the title character, for which he received both praise and criticism from critics alongside a Golden Globe nomination. For his next feature film, Carrey starred opposite Jennifer Aniston and Morgan Freeman in Tom Shadyac's international hit comedy Bruce Almighty (2003). Carrey played a television newsman who unexpectedly receives God's omnipotent abilities when the deity decides to take a vacation. The film received mixed reviews upon release but still became a financial success, earning over $484 million worldwide, and going on to become the seventeenth highest-grossing live action comedy of all time. In 2004, Carrey starred in Eternal Sunshine of the Spotless Mind. The film received critical acclaim upon release. Critics highly praised Carrey's portrayal of Joel Barish, in addition to the performance of his co-star Kate Winslet, who was nominated for an Oscar.
== History == Zalcitabine was first synthesized in the 1960s by Jerome Horwitz and subsequently developed as an anti-HIV agent by Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan at the National Cancer Institute (NCI). Like didanosine, it was then licensed because the NCI may not market or sell drugs. The National Institutes of Health (NIH) thus licensed it to Hoffmann-La Roche.
== Relationship to elasticity == The elastic modulus of a material is not the same as the stiffness of a component made from that material. Elastic modulus is a property of the constituent material; stiffness is a property of a structure or component of a structure, and hence it is dependent upon various physical dimensions that describe that component. That is, the modulus is an intensive property of the material; stiffness, on the other hand, is an extensive property of the solid body that is dependent on the material and its shape and boundary conditions. For example, for an element in tension or compression, the axial stiffness is
Cell biology is the branch of biology that studies the structure, function, and behaviour of cells. Bioenergetics is a field in biochemistry and cell biology that concerns energy flow through living systems. This is an active area of biological research that includes the study of the transformation of energy in living organisms and the study of thousands of different cellular processes such as cellular respiration and other metabolic and enzymatic processes that enable the use of energy. Genetics is the scientific study of inheritance. Classical genetics, specifically, is the study of how genes and traits are passed on from parents to offspring; its principles are called Mendelian inheritance. A Punnett square can be used to predict the results of a test cross. The chromosome theory of inheritance, which states that genes are found on chromosomes, was supported by Thomas Morgans's experiments with fruit flies, which established the sex linkage between eye color and sex in these insects.
The GRP RNA motif is a conserved RNA structural element identified in introns of glycine-rich RNA-binding protein genes, including GRP7 and GRP8. It is associated with alternative splicing and nonsense-mediated decay (NMD). GRP RNA motif has been reported as a cis-regulatory element, that modulates binding of GRP7 and GRP8 proteins to their RNA targets. The motif is predicted to form a stem-loop structure of approximately 20 base pairs. An alternative 5′ splice site is located near the base of the stem, suggesting that RNA structure may influence splice-site accessibility. In Arabidopsis thaliana (At), AtGRP7 and AtGRP8 are circadian clock-regulated RNA-binding proteins that form an interlocked auto-regulatory and cross-regulatory feedback network based on alternative splicing and NMD of their own pre-mRNAs, contributing to circadian output regulation, were transcript levels oscillate with a daily rhythm. GRP7 and GRP8 are also involved in regulating flowering time. Homologous motifs of GRP RNA motif have been identified in multiple plant species within the Pentapetalae clade.
Sources: en.wikipedia.org
In 1934, Willard Libby reported that he had found weak beta activity in pure neodymium, which was attributed to a half-life over 1012 years. Almost 20 years later, it was claimed that the element occurs in natural neodymium in equilibrium in quantities below 10−20 grams of promethium per one gram of neodymium. However, these observations were disproved by newer investigations, because for all seven naturally occurring neodymium isotopes, any single beta decays (which can produce promethium isotopes) are forbidden by energy conservation. In particular, careful measurements of atomic masses show that the mass difference between 150Nd and 150Pm is negative (−87 keV), which absolutely prevents the single beta decay of 150Nd to 150Pm. In 1965, Olavi Erämetsä separated out traces of 147Pm from a rare earth concentrate purified from apatite, resulting in an upper limit of 10−21 for the abundance of promethium in nature; this may have been produced by the natural nuclear fission of uranium, or by neutron capture of 146Nd. Both isotopes of natural europium have larger mass excesses than sums of those of their potential alpha daughters plus that of an alpha particle; therefore, they (stable in practice) may alpha decay to promethium. Research at Laboratori Nazionali del Gran Sasso showed that europium-151 decays to promethium-147 with the half-life of 5×1018 years; later measurements gave the half-life as (4.62 ± 0.95(stat.) ± 0.68(syst.)) × 1018 years. It has been shown that europium is "responsible" for about 12 grams of promethium in the Earth's crust.
==== Unfavorable public opinion ==== Polling indicates that a majority of Americans opposed its previous provisions to ban state regulation of artificial intelligence. The provision was seen as irresponsible by researchers who believe that artificial superintelligence is imminent. Others feared that it would have prevented regulation of AI-generated child pornography and deepfakes, made certain privacy laws obsolete, and further centralized power in the federal government. Representative Marjorie Taylor Greene (R-GA) stated that she would have voted against the bill if it had returned to the House with the restrictions on AI legislation.
== Description == Parkia biglobosa is a dicotyledonous angiosperm belonging to the family Fabaceae (Caesalpinioideae - Mimosoid clade). It is a deciduous perennial that grows to between 7 and 20 metres high, in some cases up to 30 metres. The tree is a fire-resistant heliophyte characterized by a thick dark gray-brown bark. The pods of the tree, commonly referred to as locust beans, are pink in the beginning and turn dark brown when fully mature. They are 30-40 centimetres long on average, with some reaching lengths of about 45 centimetres. Each pod can contain up to 30 seeds; the seeds are embedded in a sweet, powdery yellow pulp.
For a soleus receptor, Houk and Simon obtain average values of K=57 pulses/sec/kg, A=0.31, a=0.22 sec−1, B=0.4, b=2.17 sec−1, C=2.5, c=36 sec−1 . When modeling a cat stretch reflex, Lin and Crago improved upon this model by adding a logarithmic nonlinearity before the Houk and Simon model and a threshold nonlinearity after.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.